Study details
Enrolling now
AGN-193408 SR Trial
AbbVie
NCT IDNCT04499248ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
96
Study length
about 8.3 years
Ages
18+
Locations
42 sites in AZ, CA, CT +18
What this study is about
Researchers are testing AGN-193408 SR in people with open-angle glaucoma or ocular hypertension. The trial will evaluate the safety and effectiveness of this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Lumigan
- 2.Lumigan Vehicle
- 3.Sham Administration
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye, Number of participants experiencing treatment emergent adverse events
Body systems
Cardiology / Heart